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Abstract decrease was observed after the inhibition of NO
synthesis. Histological examination of the kidney speci-Background. The pathophysiology of renal ischaemia,
resulting in tubular cell injury and leading to acute mens showed that morphological changes were least
in the rats treated with -arginine, when comparedrenal failure (ARF), remains unclear. An ever-
increasing number of investigations focus on a possible with all other groups with ARF. Nevertheless, the
lesions were most prominent in the -NAME+ARFrole of nitric oxide (NO) in regulating circulation
during ARF. In this context, we investigated the influ- group. In this group, the areas of corticomedullar
necrosis were more widespread in comparison withence of chronic stimulation or inhibition of NO syn-
thesis, or both, on haemodynamic parameters, other groups, especially the -arginine group where
only swelling of the proximal tubular cells washistology and plasma renin activity (PRA) after isch-
aemia–reperfusion injury of rat kidneys. observed. Treatment with -NAME was not accom-
panied by any significant alteration in the plasmaMethods. Experiments were performed on adult, male
Wistar rats. Before induction of ARF, a group of concentration of angiotensin I (ANG I), while in the
group treated with -arginine ANG I had a tendencyanimals was treated with a NO synthesis inhibitor (-
NAME) and another group was treated with a pre- to decrease.
Conclusions. Acute post-ischaemic renal failure maycursor of NO synthesis (-arginine). The animals
received those substances for 4 weeks. Control groups be alleviated by administering the NO substrate (-
arginine). NO acts cytoprotectively on tubular epithe-received the same amount of tap water for 4 or 8
weeks and were divided into groups with ARF (4 lial cells in ischaemia–reperfusion injury of rat kidney.
Evidence of this comes from both histopathologicalweeks–ARF group and 8 weeks–ARF group) and a
sham-operated group. Another group of rats was findings and increased tubular water and sodium
reabsorption. However, inhibition of NO synthesistreated first with -NAME and then with -arginine
in their drinking water, for 4 weeks for each of these (provoked by -NAME) worsens renal haemo-
dynamics and aggravates morphological changes aftertwo substances. All parameters were evaluated 24 h
after the induction of ischaemic ARF or the sham ARF. These aggravations can, however, be reversed
by -arginine.operation.
Results. Our results show that such long-term stimula-
Key words: acute renal failure; angiotensin I; haemo-tion of NO release by -arginine improved renal
dynamics; nitric oxide; renal morphologyhaemodynamics in the ischaemic form of ARF. Renal
blood flow (RBF) increased by 96% in the -arginine-
treated rats with ARF compared with the group with
ARF alone. Inhibition of NO synthesis worsens renal Introduction
haemodynamics after ARF. However, this aggravation
can be reversed by -arginine. The rate of water
Nitric oxide (NO), an endothelium-derived relaxingreabsorption was reduced in all groups with ARF, but
factor, is produced mainly from -arginine, which isthis reduction was least in the group treated with -
mediated by NO synthases. Previous reports havearginine. The rate of Na+ reabsorption was reduced
shown that NO plays an important role in thein all groups 24 h after renal ischaemia, but a significant
regulation of systemic and renal haemodynamics [1,2].
NO may have a role to play in the pathophysiologicalCorrespondence and offprint requests to: M. Jerkić, c/o Marko
mechanisms in different renal diseases [3,4], but theVojvodic, 304 4420–106 Street, Edmonton, T6H 4W9 Alberta,
Canada. mechanism of its action on the circulation in acute
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the drinking water, for 4 weeks for each of these tworenal failure (ARF) has yet to be elucidated. In
substances (-NAME+-Arg+ARF group).addition, the effects of NO on tubular morphology
Group 6:and function are even less clearly understood. Hence,
control rats (n=16) for the previous group of animals.studies on the role of NO synthesis in the regulation
They received tap water for 8 weeks and then wereof the renal blood flow and function are of high subjected to ARF (8 weeks–ARF group).
pathophysiological and therapeutic relevance. Besides,
Blood pressure and body mass were measured once a weekdecreased synthesis or action of NO has been implic-
during the 4- and 8-week course of treatment respectively.ated in some other diseases, such as hypertension,
Before the induction of ischaemic ARF, endothelium-hypercholesterolaemia, diabetes or atherosclerosis [5]. dependent NO-mediated vasodilatation was examined using
This study was designed to investigate whether chronic acetylcholine (Ach). Animals were anaesthetized using intra-
manipulation of the NO system (stimulation or peritoneal sodium pentobarbital (Nembutal ), 35 mg/kg b.m.
inhibition of NO synthesis, or both) influences isch- The femoral artery (for blood pressure measurement) and
aemia–reperfusion injury of rat kidneys, as seen femoral vein were cannulated and Ach was administered as
through its haemodynamic and histopathological three i.v. boluses (0.2 mg/kg b.m., 0.4 mg/kg b.m. and
0.6 mg/kg b.m.). Boluses were separated by time intervalsparameters.
allowing mean arterial pressure (MAP) to return to theEvidence is also emerging that NO contributes to
baseline value. MAP was measured with a pressure trans-the regulation of renin secretion. Therefore, this was
ducer and recorded on a direct writing recorder. Vasodilativeamong our topics for investigation. A functional inter-
response to Ach was calculated for each animal as a percent-action between NO and the renin–angiotensin system age of the MAP decline from its baseline value. After a
might be expected since the effects of NO on systemic 30-min wash-out interval and recovering of MAP, ARF was
and renal haemodynamics appear to be opposite to induced. The right kidney was removed, and the left renal
those of angiotensin II. It has been shown [6,7] that artery was gently separated from the renal vein and clamped
the plasma renin activity is increased in the initial with an atraumatic clamp for 45 min. The sham-operated
stages of ARF. In this context, we examined whether rats were right nephrectomized. Immediately after surgery
all rats were placed in individual metabolic cages and urinea long-term manipulation of the NO system changed
was collected for the next 24 h. On the last experimental daythe plasma renin activity (PRA) in the early stage of
the treated animals continued to receive the same amount ofpost-ischaemic ARF.
the -NAME or -arginine as they did previously. The water
and thus the drug intake were measured.
Subjects and methods
Haemodynamic measurements 24 h after reperfusion
Experiments were performed on adult male Wistar rats Haemodynamic parameters were measured after urine collec-
(200–250 g). All animals were given standard food for labor- tion in anesthetized (35 mg/kg sodium pentobarbital ) rats:
atory rats (Veterinarski zavod, Zemun, Yugoslavia). Two sham-operated rats (n=10), 4 weeks–ARF group (n=14),
separate baseline determinations of body mass and systolic -NAME+ARF group (n=8), -Arg+ARF group (n=8),
blood pressure were made in all rats over a period of 2 -NAME+L-Arg+ARF group (n=8) and the respective
weeks. Using a tail-cuff, pneumatic pulse detector and a control animals, 8 weeks–ARF group (n=8). Blood pressure
direct recorder (Physiograph Four, Narco Bio-System, was measured directly through a femoral artery catheter
Houston, TX, USA) systolic blood pressure was measured (PE-50, Clay-Adams, Parsippany, NJ, USA), using a low-
indirectly. The animals were divided into six groups (as volume displacement transducer (P23 Db; Statham, Oxnard,
follows) according to the drugs they were given during the CA, USA) and a direct writing recorder. MAP was obtained
treatment period (of 4 or 8 weeks). All animals were eventu- by electronic integration. Cardiac output (CO) was deter-
ally subjected to ARF, with the exception of the sham- mined using a previously described [8] modification of
operated rats (see Fig. 1A outlining the experiment). Coleman’s application of the dye dilution technique [9].
Total peripheral resistance (TPR) was calculated from MAPGroup 1:
and CO (assuming that mean right atrial pressure is zero).sham-operated rats (n=18) received tap water—
For the blood-flow measurement the left renal artery was100 ml/kg body mass (b.m.) for 4 weeks.
gently separated. An ultrasonic flow probe (1RB, internalGroup 2:
diameter=1 mm) was placed around the artery to measurecontrol rats (n=22) received the same amount of tap
the total renal blood flow (RBF), using a Transonic T106water for 4 weeks and then ARF was induced (4
Small Animal Flowmeter (Transonic System Inc., Ithaca,weeks–ARF group).
NY, USA). Renal vascular resistance was calculated byGroup 3:
dividing MAP by renal blood flow.-NAME (NG--arginine methyl ester; 10 mg/kg
b.m./day), a NO synthesis inhibitor, was given in the
drinking water for 4 weeks (-NAME+ARF group, Biochemical measurements and morphology
n=16).
Group 4: Urinary and plasma creatinine concentrations were deter-
mined using a Beckman 42 spectrophotometer. Concen--arginine (2 g/kg b.m./day), a substrate for NO was
given in the drinking water for 4 weeks (-Arg+ARF trations of sodium (Na+) and potassium (K+) in the plasma
and urine were measured using a IL 943-flame photometergroup, n=16).
Group 5: (Instrumentation Laboratory, Milan, Italy). A standard for-
mula was used to calculate creatinine clearance. Fractionalrats (n=16) were treated first with -NAME (10 mg/kg
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creatinine clearance. Reabsorption rates of Na+ and water
at tubular sites were calculated using the formulae quoted in
Kusaka et al. [10].
Histological examination of the left kidney was also made
24 h after reperfusion. The renal tissue was fixed in 10%
buffered formalin solution. Later, the kidney was dehydrated
in alcohol, blocked in paraffin wax and 5-mm-thick sections
were cut and stained by periodic acid-Schiff reaction. Light
microscopy (LM ) evaluations were made so those acute
tubular lesions were graded on a scale from 0 to 4+
according to the degree of severity:
0=normal tubular cells,
1+=loss of luminal membrane or brush borders,
2+=swelling and vacuolization of cells,
3+=separation of cells from the basement membrane,
4+=as 3+ with nude basement membrane.
The severity of congestion, i.e. the accumulation of red
blood cells in glomeruli, peritubular capillaries and intrarenal
veins, was graded on a scale from 1+ to 3+ as described
by Mandal et al. [11]. The presence of tubular dilatation,
cast formations, mononuclear infiltration and interstitial
oedema was noted with 1, and their absence with 0. Vascular
changes (in arterial vessel walls) were graded according to a
scoring system proposed by Mandal and co-workers [12].
The sum of these changes was the histopathological score
for comparison between the groups.
Two independent investigators made histological evalu-
ations; if their assessment disagreed, consensus was reached
by discussion, whereas for the histopathological score the
mean value was calculated for each group.
In the remaining rats from each group (n=8), PRA levels
were measured. To determine PRA, animals were guillotined
Fig. 1. (A) Experiment outlined; (B) systolic blood pressure duringand blood samples collected into chilled, siliconized, centri- 4 or 8 weeks before induction of ARF in: control rats, -NAME
fuge tubes containing Na2EDTA (2 mg/ml ). REN-CT2 treated rats, -arginine treated rats and rats treated first with -angiotensin I radioimmunoassay (RIA) kit (CIS Bio NAME and then with -arginine.
International, France), were used in radioimmunoassay
procedures.
arginine, systolic blood pressure was significantly
higher during the treatment with -NAME and then
Statistical analyses decreased slowly in the period when the rats received
-arginine reaching the control level at the end of theResults are expressed as mean±SEM. One-way analysis of
treatment (Figure 1B).variance (ANOVA) was applied. When the ANOVA results
Ach had a vasorelaxant effect. The effect was gener-were significant, Bonferroni’s t-test was used to determine
ally dose dependent, except for the greatest dose in thethe level of significance where a P-value <0.05 was consid-
ered to be significant (Primer of Biostatistics, by Stanton control group and the group pretreated with -arginine.
A. Glanz). It can be clearly seen in Fig. 2A that the vasorelaxant
effect in rats pretreated with -NAME is considerably
less than (and significantly different from) the effect in
Results all other groups. However, in rats pretreated first with
-NAME and then with -arginine, the effect is clearly
pronounced and strongly dose dependent.Treatment with -NAME, -arginine or both had no
influence on body mass. The systolic blood pressure Blood pressure during ARF-induction is shown in
Fig. 2B. MAPs before and after clamping are notwas significantly higher 1 week after the beginning of
treatment with -NAME and was still elevated by the significantly different. After the moment of clamping
the pressure decreased insignificantly in the rats of allend of the experiment, whereas in the groups not
receiving NO synthesis inhibitor systolic blood pressure groups, and above all in rats pre-treated with -
NAME.remained unchanged (Figure 1B). In the -arginine-
treated rats, systolic blood pressure was slightly The systemic haemodynamic parameters, SHP
(MAP, CO and TVR) for all groups are summarizedlowered only 4 weeks after the beginning of the treat-
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Fig. 3. Mean blood pressure, cardiac output (CO) and total vascular
resistance (TVR) in: sham-operated rats, control rats with acute
renal failure (4 weeks – ARF ), -NAME-treated ARF rats, -argin-
ine treated ARF rats, rats treated first with -NAME and then with
-Arg (-NAME+ -Arg+ARF group), and in rats of the (8
weeks – ARF) group, serving as a control for the last group; *P<0.05
compared with sham-operated rats; §P<0.05 compared with respect-
ive ARF control.Fig. 2. (A) Concentration-response to acetylcholine (Ach) in: control
rats, -NAME treated rats, -arginine treated rats and rats treated
first with -NAME and then with -arginine. (B) Mean blood
-arginine induced, however, a significant increase inpressure during ARF-induction in: sham-operated rats, control rats
with acute renal failure (4 weeks – ARF), -NAME-treated ARF the RBF after ARF, in comparison with all other
rats, -arginine treated ARF rats, rats treated first with -NAME groups with ARF. Moreover, the RBF rose by 27% in
and then with -Arg (-NAME+-Arg+ARF group), and in rats the -Arg+ARF group with respect to the sham-of the (8 weeks – ARF) group, serving as a control for the last group.
operated group. The RVR was lowered slightly in this
group, in comparison with the control groups with
ARF and the sham-operated group, and was reduced(i) the SHP were not altered 24 h after reperfusion in
either control group with ARF when compared with markedly, compared with the -NAME+ARF group
(Figure 4).the sham-operated rats; (ii) in neither the -Arg+ARF
group nor in the -NAME+L-Arg+ARF group was Biochemical parameters are shown in Table 1. No
significant differences in plasma sodium concentrationthe SHP improved; (iii) treatment with -NAME
noticeably increased the MAP and TVR in comparison were found between the groups. There was an increase
in plasma potassium concentration in all groups 24 hwith all other groups.
Changes in haemodynamic parameters in the renal after renal ischaemia when compared with the sham-
operated group. In the -NAME+ARF group theartery are shown in Figure 4. After the induction of
ARF, in both control ARF groups (4 weeks–ARF and increase in plasma concentration of K+ was signific-
antly higher compared with the relevant 4 weeks–ARF8 weeks–ARF) the RBF was reduced by 35% compared
with the sham-operated animals, but the difference was control group. Creatinine clearance decreased in all
groups after AFR, but there were no significant differ-not significant. The renal vascular resistance (RVR)
was slightly higher after inducing ARF in both control ences among the groups. Fractional excretion of Na+
and K+ increased 24 h after renal ischaemia in allARF groups. -NAME-induced inhibition of NO syn-
thesis caused a significant decrease of the RBF in those groups. The highest increase in fractional excretion of
sodium was observed in the -NAME+ARF group.animals, compared with that of sham-operated rats;
and a significant increase of the RVR, in comparison The reabsorption rate of water was reduced in all
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statistically significant in the -Arg+ARF group in Histological examination of the kidney specimens
comparison with the sham-operated group. The reab- obtained 24 h after ARF revealed that rats treated
sorption rate of Na+ was also reduced in all groups with -arginine had minor morphological changes in
24 h after renal ischaemia and a large decrease was comparison with all other groups with ARF
observed after inhibition of NO synthesis. (Figure 5A). Moreover, there was no significant mor-
phological difference between this group and the sham-
operated group. However, the -NAME+ARF group
had significant tubulointerstitial, arteriolar and glomer-
ular lesions. Tubulointerstitial lesions in this group
were widespread and intensive and they were character-
ized by extensive tubular necrosis in the corticomedul-
lar area (Figure 6A). In addition, dilatation of lumina
of distal tubuli with huge PAS positive tubular casts
was also found to be characteristic of the -
NAME+ARF group. In contrast, in the -
arginine+ARF group only the swelling of proximal
tubular cells and different degrees of interstitial oedema
were found (Figure 6B). Concerning glomeruli, the -
NAME+ARF group had the most prominent mor-
phological changes. We noticed an increase in both the
mesangial matrix and cells in all glomeruli, and in
addition, in some glomeruli we revealed mesangial
sclerosis or fibrinoid necrosis (Figure 6A). In the -
NAME group without ARF, minor abnormalities of
glomeruli were detected, such as a slight increase of
the mesangial matrix with or without mesangial cell
proliferation. These findings are correlated with those
on the morphology of blood vessels. However, the
glomeruli of the -arginine group were almost indistin-
guishable from those of the sham-operated group. A
slight increase of mesangial cell proliferation is rarely
observed in this group (Figure 6B). The blood vessels
of rats treated with -NAME after inducting ischaemic
ARF showed a wide range of morphological changes;
from minor ones such as swelling and proliferation of
myointimal cells, to extensive ones such as fibrinoid
necrosis (Figure 7A). Before ARF was induced the
rats pretreated with -NAME had some evident mor-
Fig. 4. Renal blood flow (RBF ) and renal vascular resistance (RVR) phological abnormalities of the blood vessels, such as
in: sham-operated rats, control rats with acute renal failure (4 vacuolization of myointimal cells, foam transformation
weeks – ARF ), -NAME-treated ARF rats, -arginine treated ARF of media, or even myoelastofibrosis in two cases. Thus,rats, rats treated first with -NAME and then with -Arg (-
the blood vessel lesions in -NAME rats were moreNAME+ -Arg+ ARF group), and in rats of the (8 weeks – ARF)
group, serving as a control for the last group. pronounced after ARF than before it. In -arginine-
Table 1. Biochemical parameters in: sham operated rats, control rats with ARF (after 4 and 8 weeks), -NAME treated rats with ARF, -
arginine-treated rats with ARF and rats with ARF, treated with both -NAME and -arginine
Sham ARF–4 weeks -NAME+ARF -Arg+ARF -NAME+- ARF–8 weeks
(n=10) (n=14) (n=8) (n=8) Arg+ARF (n=8)
(n=8)
PNa+ (mmol/l ) 142.0±2.1 144.27±0.61 143.3±1.1 139.9±2.4 136.1±1.2 137.4±1.0
PK+ (mmol/) 3.5±0.1 3.92±0.12 5.01±0.411,2 4.72±0.231 4.67±0.241 4.88±0.231Urine flow (l/min/kg) 13.8±1.1 14.7±1.8 12.6±2.3 11.2±3.5 15.8±2.6 12.0±3.0
CCRE (ml/s/kg) 44.1±4.5 2.93±0.641 1.31±0.451 1.01±0.111 2.12±0.251 4.0±1.51
FENa+ (%) 0.17±0.09 2.91±0.72 7.2±1.71,2 6.4±1.31 4.36±0.51 1.55±0.54
FEK+ (%) 34.4±2.2 275±441 265±291 330±211 230±221 163±33Reabsorption rate of H2O (%) 99.48±0.04 86.3±2.21 87.2±2.21 92.18±0.83 88.6±1.51 91.9±2.1Reabsorption rate of Na+ (%) 99.86±0.05 97.09±0.72 90.2±3.01,2 93.6±1.31 95.64±0.51 97.2±1.4
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A
B
Fig. 6. (A) Necrotic glomerulus and tubuli ( left) in comparison to
the well preserved glomerulus (right) with slight mesangial cell
proliferation in -NAME treated rats with ARF (× 320); (B) Almost
normal glomerulus with slight mesangial cell proliferation and slight
increase of mesangial matrix in -arginine treated rats with ARF;
Fig. 5. (A) Histopathological score and (B) Plasma concentration swelling of the proximal tubular cells is also shown (× 400).
of angiotensin I (ANG I) in: sham-operated rats, control rats with
acute renal failure (4 weeks – ARF), -NAME – treated rats before
and after ARF, -arginine treated ARF rats, rats treated first with
-NAME and then with -Arg (-NAME+ -Arg+ARF group), Ref. [13]). What we have found is a considerably
and in rats of the (8 weeks – ARF) group, serving as a control for weaker response to Ach in rats pretreated with -
the last group. NAME. This can be taken as a strong indication of
the NO synthesis inhibition in -NAME-pretreated
treated rats slight necrotic arteriolar lesions were rarely animals. However, even though the response was weak
detected (Figure 7B). it did not disappear completely because Ach may act
Figure 5B shows that 24 h after ARF the plasma on the endothelium in ways that are not NO synthase-
concentration of angiotensin I (ANG I) was slightly dependent, such as by releasing the endothelial-derived
but non-significantly higher in the 4 weeks–ARF rats hyperpolarizing factor (EDHF).
when compared with the sham-operated rats. The Our results have shown that long-term stimulation
treatment with -NAME was not accompanied by any of NO release by -arginine improves renal haemo-
significant alteration in the plasma concentration of dynamic parameters in the ischaemic form of ARF,
ANG I, while in the group treated with -arginine, whereas they are worsened by the inhibition of NO
PRA had a tendency to fall in relation to the relevant synthesis. We also showed that this aggravation
4 weeks–ARF control group. As for the -NAME+L- provoked by -NAME can be reversed by -arginine.
Arg+ARF group, the circulating level of ANG I was These observations parallel those of Rivas-Cabañero
not different when compared with the respective 8 et al. [13], showing that NO inhibition aggravates
weeks–ARF control animals. gentamicin-induced renal failure in rats, and that of
Schramm et al. [15] and Schmidt et al. [16 ], demon-
strating beneficial effects of NO on the renal function
Discussion in toxic ARF, produced in rats with uranyl nitrate.
Chintala and co-workers [17] found that acute
inhibition of endothelial-derived relaxing factorTo test the view that chronic administration of -
NAME inhibits NO synthesis, we examined the vaso- (EDRF) aggravates ischaemic acute renal failure in
anesthetized rats. The experimental protocol in theirrelaxant effect of Ach (this effect is often used as an
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M. Jerkić et al.1404
inhibition or stimulation on the systemic
haemodynamics.
This study has shown, however, that renal haemo-
dynamic alterations induced by ARF, where NO syn-
thesis was inhibited by -NAME, were worse than
those induced by ARF alone. The aggravation of the
ischaemia-induced renal vasoconstriction caused by -
NAME suggests that endogenous NO is functionally
present and may be an important mediator regulating
renal haemodynamic parameters in ARF. Conger et al.
[20] demonstrated that endothelium-dependent relaxa-
tion is clearly impaired after ischaemia. In a recent
publication [21] however, these authors concluded that
NOS/NO activity is in fact highest above baseline
1-week after norepinephrine-induced ARF and cannot
be increased further by exogenous stimuli of NOS
activity. Schramm et al. [15] suggested that renal
ischaemia, which injures endothelial cells, reduced the
production of NO in them. On the contrary, Chintala
et al. [17] summarized that synthesis of EDRF is
probably turned on maximally by the ischaemic insult
because treatment with -arginine resulted in only a
modest improvement of RPF and GFR in the isch-
aemic kidney. In our study however, long-term
treatment with -arginine resulted in a marked increase
in the renal blood flow 24 h after renal ischaemia.
Namely, RBF became increased by 96% in the -
arginine-treated rats with ARF compared with the
group with ARF alone (Figure 4). This strongly sug-
gests that release of NO does not reach its maximum
A
B
24 h after ischaemia–reperfusion injury.Fig. 7. (A) Segmental fibrinoid necrosis of inerlobar artery with
collapsed glomerulus in -NAME treated rats with ARF (× 320); Creatinine clearance, CCRE, is not significantly(B) Intensive interstitial oedema with necrosis of the small artery in different among groups with ARF, irrespective of their
-arginine treated rats with ARF (× 250). treatment, and is lowest in -arginine-pretreated rats
with ARF. This is because CCRE is not a suitableindicator of glomerular filtration in rats treated withistered an NO synthase inhibitor (NG-monomethyl--
arginine, -NMMA) or NO precursor (-arginine), or -arginine (and only in them) since creatinine arises as
a waste product in the decay of -arginine. However,both of them in an infusion that started 30 min before
the occlusion of the left renal artery ( lasting 40 min) it seemed almost inconceivable to add a more appro-
priate method, e.g. determination of inulin clearance,and continued throughout the experiment (220 min).
The authors found that NO synthesis inhibition exacer- to our procedure, which was already very difficult for
the animals.bated ischaemia-induced changes in renal function,
whereas the infusion of -arginine resulted in improved From definitions of the reabsorbtion rates of Na
and water, stems the idea that an increase in creatininerenal plasma flow (RPF) and glomerular filtration rate
(GFR) in the ischaemic kidney. clearance increases both of them. This means that they
are actually both greater in ARF rats treated with -In our experiments chronic application of -NAME,
4 weeks before the induction of ARF, resulted in a arginine than their values calculated by using measured
creatinine clearance. Nevertheless, the reabsorptionsignificant rise in systolic blood pressure, as described
previously by Baylis et al. [18] and Oliviera et al. [19], rate of water and Na+ was higher in ARF rats treated
with -arginine than in -NAME-treated rats withsuggesting that -NAME was effective in inhibiting
NO synthesis. ARF (Table 1). Moreover, the reabsorption rate of
water in the -arginine group was not different com-Induction of ARF did not significantly alter the
systemic haemodynamic parameters (SHP). In the pared with the sham-operated group. These effects of
-arginine are most likely produced by stimulatingARF group treated with -NAME, MAP and TVR
increased, while CO had a tendency to decrease reabsorption of water and Na+ at the tubular site.
This hypothesis was substantiated by histopathological(Figure 3). However, the same changes of those para-
meters were observed in the -NAME-treated rats findings in the -arginine group where only swelling of
the proximal tubular cells was observed (Fig. 6B).without ARF (unpublished data). In neither group,
i.e. the -Arg+ARF and the -NAME+-Arg+ARF, Along the same lines, Negita and co-workers [22]
reported that vacuolization and desquamation of epi-were the SHP improved. It can be concluded that ARF
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after reperfusion in groups treated with -arginine or To conclude, acute post-ischaemic renal failure may
be alleviated by administering the NO substrate (-sodium nitroprusside compared with those in the con-
trol ARF group and the group treated with -NAME. arginine) and NO acts cytoprotectively in ischaemia–
reperfusion injury of rat kidneys.In this study, the left renal artery and vein were
clamped for 90 min and the animals were treated either The improvement in the course of ARF due to the
administration of -arginine observed in this studywith a NO synthesis inhibitor or with two stimulators
during various periods before reperfusion. implies that the administration of the NO synthesis
donor to patients with ARF would yield a favourablePrevious studies have indicated that there is a grow-
ing ambiguity about the role of NO and its metabolic effect.
However, all parameters of the ARF are obviouslyproduct peroxinitrite (ONOO−) in the pathophysiology
of ARF. ONOO− is thought to mediate the toxic worse in rats with chronic inhibition of the NO syn-
thesis. This indicates that a considerably poorer courseaction of NO and superoxide anion in hypoxia–reper-
fusion injury of different organs, including the kidney of ARF can be expected in all diseases in which either
synthesis and/or action of NO is decreased chronically.[23]. But the efficiency of peroxinitrite-dependent reac-
tions was found to be highest at equimolar concentra- Further support for this conclusion comes from mor-
phological changes, found in kidneys, in the grouptions of O2− and NO, which suggested that an excessof either reactant could protect against peroxinitrite in treated with -NAME before induction of ARF: minor
abnormalities of glomeruli, vacuolization of myointi-vivo [24]. This finding lead Bartosz [24] to conclude
that the common opinion (‘small amounts of NO are mal cells and foam transformation of blood vessel
media. When ARF is induced in the group pre-treatedbeneficial while large amounts of NO are toxic’) should
be revised since higher doses of NO may suppress with -NAME, however, morphological changes in all
renal structures are much stronger than in the groupperoxinitrite reactions. Xia et al. [25] experimented
with NOS-transfected human renal tubular epithelial with ARF only. This also may contribute to the
understanding of the high mortality in ARF.cells and found that elimination of -arginine from the
medium resulted in ONOO− production and cell Numerous authors who investigated mechanisms of
NO activity have shown [27,28] that NO plays aninjury. However, some experiments in vitro showed
that two NO synthesis inhibitors, -NAME and - important role in the regulation of endocrine functions
(e.g. control of the secretion of pancreatic, hypothal-NMMA, protected renal tubular epithelium against
hypoxic injury. Nevertheless, the results obtained in amic, pituitary and other hormones). It was shown
that NO inhibits the synthesis of endothelin [29].experiments in vivo showed the opposite. Namely,
administration of nonselective NO synthesis inhibitors Nevertheless, our previous experiments suggested that
NO is not involved in endothelin release caused byfurther compromised renal function in various models
of ARF in vivo [13,17,22]. Noiri et al. [26 ] reasoned ARF [30]. Evidence is also emerging that NO contrib-
utes to the regulation of the secretion of renin, whichthat the existing uncertainty about the role of NO in
ARF is in part due to a lack of selective NOS inhibitors. was among the topics of our investigation.
The data obtained in our study show that plasmaThese authors found that in vivo targeting of inducible
NOS (iNOS) with oligodeoxynucleotides protects rat concentration of ANG I was increased non-
significantly 24 h after ARF. The plasma renin activitykidney during ischaemia. When the function of all
isoforms of NOS is blocked (as with non-selective has been repeatedly shown to be increased in the initial
stages of both clinical and experimental forms of ARFinhibitor), the authors concluded, the deleterious con-
sequences of inhibiting endothelial constitutive NOS [5,7]. Although these observations are consistent with
the possibility that the renin–angiotensin system (RAS)invariably prevail over the possible benefits of inhibit-
ing iNOS. Taken together, these findings, imply that is involved in ARF, they do not establish a causal
connection between the activation of the RAS and thethe degree of injury is linked to the iNOS, while
restoration of renal function after noxious stimuli subsequent development of ARF. Furthermore, it has
been shown that the PRA may return to the controldepends on constitutive NOS.
The present communication is the first report about level although ARF still continuous to persists [31].
The effects of NO on renin release and intrarenalpost-ischaemic ARF after a long-term NO release
stimulation or inhibition. Our main finding is that, formation of ANG II remain controversial [32]. Reid
and Chiu [33] quoted some studies, their results sug-besides the improvement of renal haemodynamic para-
meters, treatment with -arginine reduces tubular cell gesting a stimulatory role for the -arginine–NO path-
way in the control of renin secretion. However, underinjury in acute post-ischaemic renal failure. This is
most clearly seen in observing tubular epithelial cell different circumstances (e.g. after long-term treatment)
blockade of NO synthesis increases renin secretion.morphology in rats treated with -arginine: the changes
found were subtle (Figure 6B). The development of hypertension in Sprague–Dawley
rats, produced by chronic treatment with -NAMEHowever, we found most prominent lesions in the
-NAME+ARF group: large areas of corticomedullar depends on intactness of RAS, but -NAME can
clearly increase blood pressure independent of anynecrosis and heavy damage of the tubular epithelial
cells with a lot of intratubular casts. But, this aggrava- involvement of ANG II, concluded Melaragno et al.
[34]. An apparent inconsistency in the above-tion of changes in renal morphology can be reversed
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NO on renin release is assumed. After an initial haemodynamics in the -arginine treated group with
ARF.transient inhibitory effect, there appears to be a delayed
but sustained stimulatory effect on renin formation
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